Director / PDMR Dealing

Summary by AI BETAClose X

Optima Health plc announced on 28 September 2026 that on 23 September 2026, nil-cost options were granted under the Performance Share Plan to directors and PDMRs, including CEO Jonathan Thomas, CFO Andy Bones, and CCO Joanne Newey. These options vest in two years, subject to continued employment and performance targets, with 50% of vested shares subject to an additional one-year holding period. A total of 560,974 ordinary shares were granted as nil-cost options to these individuals, with Jonathan Thomas receiving 284,552 options and Joanne Newey receiving 113,821 options. Additionally, awards under the 2024 share plan have been granted to senior management/PDMRs, also as nil-cost options contingent on performance hurdles.

Disclaimer*

Optima Health PLC
28 September 2026
 

Optima Health plc

 

Director / PDMR Dealing

 

Optima Health plc (Company) announces that on 23 September 2026, awards were granted under the Optima Health plc Performance Share Plan (PSP) to certain directors and PDMRs.

 

The Awards take the form of nil-cost options which vest on the second anniversary of grant, subject to certain conditions including continued employment with the group and the achievement of performance targets. 50% of the shares that vest are then subject to a further one year holding period before they can be exercised.

 

In addition, further to the information on the 2024 Share Plan set out in the Company’s Admission Document and the recent notice of Annual General Meeting, the Company confirms that awards under the 2024 share plan have been granted to a number of senior management/PDMRs. Subject to achievement of the performance hurdle, nil cost options would be granted to the relevant participants according to the plan rules.

 

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation as incorporated into the law of England and Wales, and set out more details of the transactions.

 

1.

Details of PDMR

(a)

Name

1.     Jonathan Thomas

2.     Andy Bones

3.     Joanne Newey

 

2.

Reason for notification

(b)

Position / status

1.     Chief Executive Officer

2.     Chief Financial Officer

3.     Chief Commercial Officer (PDMR)

 

(c)

Initial notification / amendment

Initial notification

3.

Details of the Issuer

(a)

Name

Optima Health plc

(b)

LEI

213800TOPWJSRCW4ON08

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) have been conducted

(a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares in the capital of Optima Health plc (Shares)

GB00BRSCY602

(b)

Nature of the transaction

Grant of an option under the PSP to acquire Shares at nil cost

(c)

Price(s) and volume

Price(s)

Volume

Nil

1.     284,552

2.    162,601

3.    113,821

 

(d)

Aggregated information

Volume

Price

560,974

Nil

(e)

Date of the transaction

23 September 2026

(f)

Place of the transaction

Outside a trading venue

 

 

 

 

 

 

Name of PDMR

Cumulative % of total value of 2024 Share Plan value (subject to performance hurdles)

 

 

Jonathan Thomas

50%

Joanne Newey

10%

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings